UNSPSC 51392805: Imazodan

This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H12N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 6PVQ5VQW24 chemically known as 3(2h)-pyridazinone, 4,5-dihydro-6-(4-(1h-imidazol-1-yl)phenyl) but generally known as imazodan, which bears US NIH Compound Identifier 55918. European Medicines Agency schedules Imazodan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08139MIG.

UNSPSC 51392805 Imazodan is a Commodity code, but the recent state and local opportunities tagged under it reflect procurement of naloxone (opioid reversal medication) and drug deactivation systems rather than imazodan specifically. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building; the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription fulfillment programs. State and local governments are using this code to buy pharmaceutical products and systems that support community health and opioid-response initiatives, with issuing bodies spanning county health departments and state human services agencies.

The code shows activity concentrated in the South, with recent solicitations from Florida and Texas. Seminole County's naloxone and deactivation-system procurement (IFB, due July 26, 2023) required electronic bid submission through the county e-Procurement portal, included delivery costs, and specified a two-year initial term with one-year renewal option and a three-month probationary period. The Texas HHS RFI (due April 3, 2026) was exploratory in nature, seeking vendor experience with direct contracting models for self-insured employers and state agencies outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity specified set-aside designations or budget ceilings. The mismatch between the code's nominal scope (imazodan, a specific pharmaceutical) and the opportunities actually posted suggests this code may see infrequent use or irregular vendor tagging in state and local procurement systems.